CIPLA — Technical + Fundamental View CMP given: ₹1,481.50 Buy

 CIPLA — Technical + Fundamental View CMP given: ₹1,481.50

Based on the latest available market data, Cipla closed around ₹1,463.80 on Aug. 7, with the 50-DMA near ₹1,423 and 200-DMA near ₹1,406. The stock is therefore trading above both moving averages, which is technically constructive.

📊 Trading Call Parameter View CIPLA CMP ₹1,481.50 Trend 🟢 Mild Bullish Action BUY on breakout / dips Entry Zone ₹1,465–₹1,485 Breakout Confirmation Above ₹1,490–₹1,502 Target 1 ₹1,540 Target 2 ₹1,600 Target 3 ₹1,680 Stop Loss ₹1,435 Risk Moderate Probability 64% Timeframe 1–15 days The immediate technical resistance is around ₹1,489–₹1,502, while important supports are around ₹1,463, ₹1,448 and ₹1,435.

🔎 Technical View Bullish case: ₹1,490–₹1,502 breakout with strong volume can open the way toward ₹1,540 → ₹1,600 → ₹1,680.

Bearish case: A sustained close below ₹1,435 would weaken the setup and could bring ₹1,400–₹1,420 into play.

At ₹1,481.50, I would not chase aggressively. The better risk/reward is either buying near ₹1,465–₹1,475 or waiting for a convincing breakout above ₹1,502.

📈 EPS & Fundamental Outlook Cipla's FY26 reported EPS was around ₹43.52, while adjusted EPS was ₹46.54. FY25 adjusted EPS was ₹60.21, so FY26 earnings were affected by a significant decline.

More importantly, Q1 FY27 consolidated profit fell 39% YoY to ₹789 crore, while revenue increased only marginally. The weakness was largely related to North American business and supply issues. India's domestic business, however, grew strongly.

My normalized EPS scenario Financial Year EPS assumption Growth view FY26 ~₹43.5 Base FY27E ₹47–₹50 ~8–15% FY28E ₹52–₹56 ~8–12% FY29E ₹57–₹62 ~8–12% These are scenario estimates, not company guidance. The key upside trigger is recovery in US profitability and continued strength in India's respiratory/cardiac/diabetes portfolio.

💰 PE Ratio & Fair Value At ₹1,481.50 against FY26 reported EPS of ~₹43.52, the trailing P/E is roughly 34×. Independent market data also puts Cipla's P/E in the low-to-mid 30s.

For valuation, I would use approximately 28–32× normalized forward EPS, rather than paying a very high multiple while earnings are temporarily under pressure.

Using FY27E EPS of ₹47–₹50:

28× PE: ₹1,316–₹1,400

30× PE: ₹1,410–₹1,500

32× PE: ₹1,504–₹1,600

🎯 Fair value ₹1,500–₹1,600 based on normalized FY27 earnings.

A more optimistic recovery scenario can justify ₹1,650–₹1,700, broadly consistent with some brokerage optimism; Citi previously maintained a ₹1,700 target.

💵 Dividend Cipla declared ₹13/share dividend for FY26. Historical dividend data shows ₹13 in FY26 versus ₹16 in FY25.

At ₹1,481.50, ₹13 dividend represents approximately 0.88% yield.

So Cipla is primarily a growth/recovery + quality pharma play, rather than a high-dividend stock.

⚠️ Main Risk The biggest near-term concern is earnings. Q1 FY27 profit declined 39%, and North American revenue fell 21%, so the stock needs an earnings recovery to sustain a higher P/E multiple.

🟢 FINAL CALL — CIPLA BUY / ACCUMULATE: ₹1,465–₹1,485 Breakout BUY: Above ₹1,502 Target: ₹1,540 → ₹1,600 → ₹1,680 Stop Loss: ₹1,435 Probability: 64% Fair Value: ₹1,500–₹1,600 Longer-term recovery value: ₹1,650–₹1,700

Risk/Reward to ₹1,600 from ₹1,481.50: about 2.6:1 against the ₹1,435 stop.

Verdict: 🟢 BUY, but preferably on ₹1,465–₹1,475 dips or a confirmed ₹1,502 breakout. At ₹1,481.50, the setup is positive but not a high-conviction chase * Shreeji Finance& Investment*